Drug Profile
AGS v
Alternative Names: AGS-v; AGS-v PLUSLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Imutex
- Developer Imutex; National Institute of Allergy and Infectious Diseases; SEEK
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Viral-infections(Prevention) in USA
- 28 Mar 2020 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in USA
- 08 Jul 2019 Phase-I clinical trials in Viral infections (Prevention) in USA (unspecified route) (NCT04009824)